{
  "id": 16717556,
  "title": "ResMed global general counsel sells $102,000 in company stock",
  "url": "https://urgent.news/2026/10/27/resmed-global-general-counsel-sells-102-000-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-27T06:16:14.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/resmed-global-general-counsel-sells-102000-in-company-stock-93CH-4974238"
  },
  "original_language": "en",
  "account": "ResMed's Global General Counsel, Michael J. Rider, sold 400 shares of the company's common stock for a total of $102,000 on October 23, 2026, following a Rule 10b5-1 plan he established in 2025. This sale reduced Rider's ownership of ResMed common stock to 12,318 shares. Despite this insider transaction, the stock price remained steady at $253.20, close to the sale price. Experts suggest the stock may be undervalued, and the company has raised its dividend for 14 consecutive years. ResMed is set to release earnings on October 29, with additional insights available through InvestingPro's Pro Research Report. The company has also attracted attention from analysts, with RBC Capital Markets upgrading its rating to Outperform and raising the price target to $262, while KeyBanc increased its target to $267, both citing the company's leadership in obstructive sleep apnea devices and accessories. Rothschild Redburn maintains a Neutral rating with a $230 target, while Stifel remains cautious with a Hold rating and a $235 target, citing potential market share pressures.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}